NeuShen Therapeutics, a Shanghai-and-Boston company, raised more than $80 million in a Series B to advance three clinical-stage brain-health programs. The funding is positioned to support development toward further clinical milestones across CNS targets. The financing reflects continued investor interest in late-stage neuroscience assets and validates the company’s strategy to run multiple programs in parallel rather than relying on a single lead compound. For the sector, the round adds to momentum around CNS franchises and may influence how competitors structure next-wave CNS clinical plans.